Obesity as a catalyst for neurodegeneration
February 27, 2026 / Obesity and Neurodegeneration / Chronic Metabolic Overload / Blood–Brain Barrier Dysfunction / Neurovascular Coupling / Cognitive Decline
Midlife obesity is increasingly linked to neurodegeneration through brain-wide metabolic, vascular, and neural reprogramming. Chronic metabolic overload disrupts neurovascular coupling, blood–brain barrier integrity, cerebrospinal fluid dynamics, and myelination, contributing to progressive cognitive decline and heightened neurological vulnerability.
Bariatric Surgery Boosts Metabolic Health in T1D and Obesity
February 26, 2025 / Type 1 Diabetes and Obesity / Metabolic Bariatric Surgery / Insulin Dose Reduction / Glycemic Control Improvement / Cardiometabolic Risk Factors
In adults with type 1 diabetes and obesity, metabolic bariatric surgery led to significant weight loss, reduced insulin requirements, modest A1c improvement, and better lipid and blood pressure control at one year, with comparable outcomes between sleeve gastrectomy and Roux-en-Y gastric bypass.
Long-Term Effects of Sleeve Gastrectomy on Super Obesity: A Retrospective Cohort Study of Weight Loss and Metabolic Recovery at Centro Médico Nacional 20 de Noviembre
March 2, 2026 / Sleeve Gastrectomy Outcomes / Super Obesity BMI >50 / Type 2 Diabetes Remission / Excess Weight Loss 24 Months / Metabolic Surgery Safety
In patients with BMI >50 kg/m², sleeve gastrectomy achieved 35% total weight loss and 59.6% excess weight loss at 24 months, with significant reductions in HbA1c and insulin resistance, high remission rates of diabetes and hypertension, and low complication rates.
How an anti-obesity drug improves metabolism beyond weight loss
February 24, 2026 / Tirzepatide Mechanism of Action / Brown Adipose Tissue Activation / GLP-1 GIP Dual Agonist / Energy Expenditure Increase / Type 2 Diabetes Metabolism
In obese mice, tirzepatide improved metabolism beyond appetite suppression by activating brown adipose tissue, increasing energy expenditure and batokine production, and enhancing glucose and lipid utilization, suggesting weight-independent metabolic and potential cardiometabolic benefits pending human validation.
Endothelial cell mitochondrial status influences the metabolism of the whole body
February 26, 2026 / Endothelial Cell Mitochondria / Metabolic Regulation / Obesity Prevention Mechanisms / Type 2 Diabetes Research / Healthy Aging Pathways
In mouse models, endothelial cell mitochondrial stress triggered adaptive systemic responses, enhancing fatty acid oxidation, glucose utilization, antioxidant defenses, and resistance to diet-induced obesity while preserving motor and cognitive function, positioning the endothelium as a novel therapeutic target in metabolic disease and aging.
Novo Nordisk, Vivtex Ink Up to $2.1B Deal to Develop Oral Biologics for Metabolic Conditions
February 26, 2026 / Oral Biologics Development / Obesity and Type 2 Diabetes / GLP-1 Receptor Agonists / Gastrointestinal Drug Delivery Platform / Novo Nordisk Vivtex Partnership
Novo Nordisk and Vivtex formed a $2.1B partnership to develop oral biologics for obesity and diabetes, leveraging advanced gastrointestinal screening and AI-driven delivery platforms to improve peptide absorption, potentially expanding access to GLP-1–based and other metabolic therapies beyond injectables.
Organochlorine pesticides and obesity in a rural prediabetic population: exploring bidirectional pathways with metabolic indicators
February 27, 2026 / Organochlorine Pesticides Exposure / Obesity Risk in Prediabetes / Beta-HCH and DDE / Cardiometabolic Biomarkers / Environmental Metabolic Disruption
In rural adults with prediabetes, organochlorine pesticide exposure—particularly β-BHC and p,p’-DDE—was associated with increased obesity risk. Bidirectional mediation analyses suggest metabolic dysfunction and obesity mutually exacerbate pesticide-related cardiometabolic and hepatic abnormalities.
Parental obesity triples risk of early liver disease in children, new study finds
March 2, 2026 / Parental Obesity and MASLD / Intergenerational Liver Disease Risk / Metabolic Dysfunction Associated Steatotic Liver Disease / Early Onset Fatty Liver / Obesity Prevention Preconception
Parental overweight or obesity at conception was associated with a more than threefold increased risk of metabolic dysfunction-associated steatotic liver disease (MASLD) in offspring by age 24, highlighting intergenerational influences on early liver fat accumulation and long-term metabolic risk.
Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity
February 24, 2026 / GLP-1 GLP-2 Dual Agonist / Dapiglutide Clinical Trial / Obesity Pharmacotherapy / Weight Loss Efficacy / Metabolic Safety Profile
In a 12-week proof-of-concept trial in adults with obesity, the dual GLP-1/GLP-2 agonist dapiglutide was well tolerated and showed favorable metabolic signals but did not achieve statistically significant weight loss versus placebo at tested doses.
New review explains how circular RNAs could unlock fat browning therapies
February 26, 2026 / Circular RNAs in Obesity / Adipose Tissue Browning / Mitochondrial and ER Stress Pathways / Type 2 Diabetes Mechanisms / Metabolic Syndrome Therapeutic Targets
A recent review highlights circular RNAs as regulators of adipose tissue browning and metabolic homeostasis, acting through microRNA sponging and organelle-specific mitochondrial and ER stress pathways, with potential as diagnostic biomarkers and therapeutic targets in obesity and type 2 diabetes.
Anti-obesity drug improves metabolism beyond weight loss, study finds
February 25, 2026 / Tirzepatide Brown Fat Activation / GLP-1 GIP Dual Agonist / Weight Independent Metabolic Effects / Brown Adipose Thermogenesis / Type 2 Diabetes Glycemic Control
In obese mice, tirzepatide reduced weight via appetite suppression but also independently activated brown adipose tissue, increasing thermogenesis and improving glycemic control beyond calorie restriction, supporting weight-independent metabolic effects of dual GLP-1/GIP receptor agonism.
Semaglutide May Reverse Damage Caused by Osteoarthritis, Study Suggests
MARch 2, 2026 / Semaglutide Osteoarthritis Treatment / Cartilage Metabolic Reprogramming / Weight Independent Joint Protection / GLP-1 Receptor Agonist / Obesity and Osteoarthritis
Semaglutide demonstrated weight-independent chondroprotective effects in osteoarthritis, reprogramming cartilage cell metabolism to enhance energy production and reduce tissue damage in mice, with supportive signals from a randomized human trial assessing pain, mobility, and joint degeneration.
BioRestorative Therapies Receives Patent Approval for Innovative Brown Adipose-Derived Stem Cell Technology Targeting Obesity and Metabolic Disorders
February 24, 2026 / Brown Adipose Stem Cell Therapy / ThermoStem Technology Patent / Obesity Regenerative Medicine / Metabolic Disorder Treatment Innovation / GLP-1 Alternative Therapy
BioRestorative Therapies received Australian patent approval for its ThermoStem® brown adipose-derived stem cell platform targeting obesity and metabolic disorders, positioning a potential cell-based alternative to GLP-1 therapies aimed at enhancing durability, metabolic efficacy, and safety pending clinical validation.
Novo Nordisk Commits Up to $2B to Drug Delivery Startup Vivtex for R&D of Oral Metabolic Meds
February 25, 2026 / Oral Peptide Drug Delivery / Obesity and Diabetes Therapies / GLP-1 Oral Formulation Innovation / Gastrointestinal Bioavailability Enhancement / Novo Nordisk Vivtex Deal
Novo Nordisk committed up to $2.1B to Vivtex to advance oral delivery technologies for metabolic therapies, leveraging AI-driven gastrointestinal screening to enhance peptide absorption and bioavailability, potentially expanding oral options for obesity and diabetes beyond current GLP-1 formulations.
Genes load the gun, lifestyle is the trigger: Study flags obesity risk among Indians
February 27, 2025 / Polygenic Obesity Risk in Indians / Lifestyle Intervention and Obesity Prevention / BMI Cutoffs in Asian Populations / Visceral Adiposity Waist to Height Ratio / Early Onset Metabolic Disease
Among Indians, high polygenic obesity risk significantly increases disease susceptibility, but healthy lifestyle behaviors—especially before age 50—substantially reduce obesity odds. Findings highlight lower BMI risk thresholds, visceral adiposity concerns, and early intervention to prevent diabetes, fatty liver, and cardiometabolic disease.
Can Poor Metabolic Health Cause Skin Cancer?
March 1, 2026 / Metabolic Syndrome and Skin Cancer / Hypertension Melanoma Risk / Obesity and Squamous Cell Carcinoma / Immune Dysfunction in Cancer / Glycolysis and Oxidative Phosphorylation
Emerging evidence links poor metabolic health—including hypertension, hyperglycemia, and obesity—to increased melanoma and nonmelanoma skin cancer risk, potentially via immune dysfunction and altered cellular energy pathways (glycolysis and oxidative phosphorylation) that may promote tumor growth.
10-Year Study Reveals Long-Term Bariatric Surgery Outcomes
February 23, 2026 / 10-Year Bariatric Surgery Outcomes / Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy / Long Term Weight Loss Durability / Insulin Resistance Predictors / Metabolic Surgery Precision Medicine
A 10-year study found both Roux-en-Y gastric bypass and sleeve gastrectomy provide durable weight loss, with RYGB showing superior long-term metabolic and glycemic improvements. Baseline insulin resistance and BMI predicted sustained outcomes, supporting precision selection of bariatric procedures.
Novo Nordisk Strikes Up to $2.1B Vivtex Deal for Oral Obesity Drugs
February 25, 2026 / Oral Biologics for Obesity / Diabetes Drug Delivery Innovation / GLP-1 Oral Therapies / Novo Nordisk Vivtex Partnership / Metabolic Disease Treatment Expansion
Novo Nordisk entered a potential $2.1B partnership with Vivtex to develop oral biologic therapies for obesity and diabetes, leveraging advanced drug delivery technologies to enhance peptide absorption and expand non-injectable GLP-1–based metabolic treatment options.
One in Four Indonesian Adults is Obese, Productive Age at Risk of Metabolic Disorders
March 2, 2025 / Obesity in Indonesia 2023 / Central Adiposity and Metabolic Syndrome / Type 2 Diabetes and Cardiovascular Risk / Sedentary Lifestyle Health Impact / Early Metabolic Screening Recommendations
Indonesia’s 2023 survey shows nearly one in four adults is obese, particularly at productive ages, driven by sedentary lifestyles and poor diet. Central adiposity increases cardiometabolic risk, underscoring the need for early screening and individualized nutrition-based interventions.